Elisa Giommoni

8PUBLICATIONS
21CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Mar 25, 2026
First-line Nivolumab plus FOLFOXIRI/Bevacizumab in advanced RAS/BRAF-mutated colorectal cancer: efficacy, safety and biomarker discovery from the phase II NIVACOR trial.

Angela Damato, Riziero Esposito Abate, Simona Tessitore

|Jan 25, 2025
Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Variants.

Michele Milella, Giulia Orsi, Mariacristina di Marco

|Jun 26, 2024
Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab-paclitaxel plus gemcitabine as second or later-line treatment.

Guido Giordano, Michele Milella, Matteo Landriscina

|Jun 06, 2023
The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma.

Letizia Procaccio, Valeria Merz, Morena Fasano

|Jan 21, 2023
Optimizing First-Line Chemotherapy in Metastatic Pancreatic Cancer: Efficacy of FOLFIRINOX versus Nab-Paclitaxel Plus Gemcitabine.

Francesco Di Costanzo, Federica Di Costanzo, Lorenzo Antonuzzo

|Jun 02, 2021
Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Study).

Elisa Giommoni, Evaristo Maiello, Vanja Vaccaro

Pageof 2

Frequent Collaborators

4 joint publications

Sara Lonardi

3 joint publications

Guido Giordano

2 joint publications

Michele Milella

2 joint publications

Serena Pillozzi